Integrated analysis of the miRNA, gene and pathway regulatory network in gastric cancer.

Gastric cancer is one of the most common malignant tumors worldwide; however, the efficacy of clinical treatment is limited. MicroRNAs (miRNAs) are a class of small non-coding RNAs that have been reported to play a key role in the development of cancer. They also provide novel candidates for targeted therapy. To date, in-depth studies on the molecular mechanisms of gastric cancer involving miRNAs are still absent. We previously reported that 5 miRNAs were identified as being significantly increased in gastric cancer, and the role of these miRNAs was investigated in the present study. By using bioinformatics tools, we found that more than 4,000 unique genes are potential downstream targets of gastric cancer miRNAs, and these targets belong to the protein class of nucleic acid binding, transcription factor, enzyme modulator, transferase and receptor. Pathway mapping showed that the targets of gastric cancer miRNAs are involved in the MAPK signaling pathway, pathways in cancer, the PI3K-Akt signaling pathway, the HTLV-1 signaling pathway and Ras signaling pathway, thus regulating cell growth, differentiation, apoptosis and metastasis. Analysis of the pathways related to miRNAs may provides potential drug targets for future therapy of gastric cancer.

[1]  K. Ghoshal,et al.  Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. , 2018, The Journal of Biological Chemistry.

[2]  J. Satayavivad,et al.  Sodium arsenite inhibited genomic estrogen signaling but induced pERα (Ser118) via MAPK pathway in breast cancer cells , 2016, Environmental toxicology.

[3]  P. Ashton-Prolla,et al.  miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma , 2016, Pancreas.

[4]  Yong Li,et al.  Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. , 2015, Critical reviews in oncology/hematology.

[5]  Yuan Wang,et al.  Exogenous hydrogen sulfide exhibits anti-cancer effects though p38 MAPK signaling pathway in C6 glioma cells , 2015, Biological chemistry.

[6]  W. Mai,et al.  MicroRNA‑34a attenuates the proliferation, invasion and metastasis of gastric cancer cells via downregulation of MET. , 2015, Molecular medicine reports.

[7]  X. Wan,et al.  Autocrine motility factor promotes epithelial-mesenchymal transition in endometrial cancer via MAPK signaling pathway. , 2015, International journal of oncology.

[8]  Zhen-hai Lu,et al.  Interleukin-8 upregulates integrin β3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-κB pathway. , 2015, Cancer letters.

[9]  Y. Doki,et al.  miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts. , 2015, Carcinogenesis.

[10]  Xian Jiang,et al.  Depletion of histone deacetylase 1 inhibits metastatic abilities of gastric cancer cells by regulating the miR-34a/CD44 pathway. , 2015, Oncology reports.

[11]  Yanqing Ding,et al.  MicroRNA-34a targets FMNL2 and E2F5 and suppresses the progression of colorectal cancer. , 2015, Experimental and molecular pathology.

[12]  Hiromu Suzuki,et al.  A Screen for Epigenetically Silenced microRNA Genes in Gastrointestinal Stromal Tumors , 2015, PloS one.

[13]  Ling-yan Guo,et al.  The effects of lanthanum chloride on proliferation and apoptosis of cervical cancer cells: involvement of let-7a and miR-34a microRNAs , 2015, BioMetals.

[14]  Raisa Uddin,et al.  Abstract B39: Targeting cancer stem cells via inhibition of PI3K/AKT pathway alone and in combination with autophagy blockade , 2015 .

[15]  L. Kowalski,et al.  Expression of apoptosis-regulating miRNAs and target mRNAs in oral squamous cell carcinoma. , 2015, Cancer genetics.

[16]  J. Byun,et al.  The expression of microRNA-34a is inversely correlated with c-MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients , 2015, Tumor Biology.

[17]  L. Yao,et al.  microRNA-34a inhibits epithelial mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through transforming growth factor-beta/Smad pathway , 2015, BMC Cancer.

[18]  Jianxing He,et al.  γ Secretase Inhibitor BMS‐708163 Reverses Resistance to EGFR Inhibitor via the PI3K/Akt Pathway in Lung Cancer , 2015, Journal of cellular biochemistry.

[19]  A. Huang,et al.  Effects of sorafenib on lung metastasis in rats with hepatocellular carcinoma: the role of microRNAs , 2015, Tumor Biology.

[20]  Yong-qiang Ren,et al.  MiR-27a Modulates Radiosensitivity of Triple-Negative Breast Cancer (TNBC) Cells by Targeting CDC27 , 2015, Medical science monitor : international medical journal of experimental and clinical research.

[21]  Xiao-Yan Xu,et al.  PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. , 2015, American journal of cancer research.

[22]  Jing Li,et al.  MiR-27a Promotes Hepatocellular Carcinoma Cell Proliferation Through Suppression of its Target Gene Peroxisome Proliferator-activated Receptor γ , 2015, Chinese medical journal.

[23]  S. Mabuchi,et al.  The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. , 2015, Gynecologic oncology.

[24]  S. S. Yadav,et al.  PI3K/AKT pathway-mediated regulation of p27Kip1 is associated with cell cycle arrest and apoptosis in cervical cancer , 2015, Cellular Oncology.

[25]  Fei Ren,et al.  MiR-20a Promotes Cervical Cancer Proliferation and Metastasis In Vitro and In Vivo , 2015, PloS one.

[26]  Pei Yang,et al.  MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype , 2015, Oncotarget.

[27]  Shufeng Zhou,et al.  Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway , 2015, Drug design, development and therapy.

[28]  Honglin Hu,et al.  rs11671784 G/A variation in miR-27a decreases chemo-sensitivity of bladder cancer by decreasing miR-27a and increasing the target RUNX-1 expression. , 2015, Biochemical and biophysical research communications.

[29]  Li-na Wang,et al.  MCP-1 stimulates spinal microglia via PI3K/Akt pathway in bone cancer pain , 2015, Brain Research.

[30]  Heng Zhang,et al.  Baicalein inhibits MMP-2 expression in human ovarian cancer cells by suppressing the p38 MAPK-dependent NF-&kgr;B signaling pathway , 2015, Anti-cancer drugs.

[31]  Kevin B. Jones,et al.  miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cells , 2015, Oncotarget.

[32]  Jin-Tang Dong,et al.  Genetic analysis and preliminary function study of miR-423 in breast cancer , 2015, Tumor Biology.

[33]  Ya-xin Lou,et al.  YSY01A, a Novel Proteasome Inhibitor, Induces Cell Cycle Arrest on G2 Phase in MCF-7 Cells via ERα and PI3K/Akt Pathways , 2015, Journal of Cancer.

[34]  Xianjun Wang,et al.  miR-27a promotes cell proliferation and metastasis in renal cell carcinoma. , 2015, International journal of clinical and experimental pathology.

[35]  C. Nicot,et al.  miR-28-3p Is a Cellular Restriction Factor That Inhibits Human T Cell Leukemia Virus, Type 1 (HTLV-1) Replication and Virus Infection* , 2015, The Journal of Biological Chemistry.

[36]  Liguo Wang,et al.  CD147 modulates autophagy through the PI3K/Akt/mTOR pathway in human prostate cancer PC-3 cells , 2015, Oncology letters.

[37]  X. Chen,et al.  A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma , 2015, Scientific Reports.

[38]  Yong-He Hu,et al.  MicroRNA‐1 promotes apoptosis of hepatocarcinoma cells by targeting apoptosis inhibitor‐5 (API‐5) , 2015, FEBS letters.

[39]  Jin-hai Tang,et al.  Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines , 2014, Molecular medicine reports.

[40]  A. Quest,et al.  PAR-3 and Syndecan-4 are involved in astrocyte adhesion induced by neuronal Thy-1 , 2015 .

[41]  S. Zappavigna,et al.  MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib. , 2015, Molecular therapy. Nucleic acids.

[42]  Jia Lu,et al.  The significance of detection of serum miR-423-5p and miR-484 for diagnosis of colorectal cancer. , 2015, Clinical laboratory.

[43]  Junfeng Zhang,et al.  Investigation of microRNA expression in human serum during the aging process. , 2015, The journals of gerontology. Series A, Biological sciences and medical sciences.

[44]  R. Bernards,et al.  Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway , 2014, Proceedings of the National Academy of Sciences.

[45]  Jun Liu,et al.  A polymorphism site in the pre-miR-34a coding region reduces miR-34a expression and promotes osteosarcoma cell proliferation and migration , 2014, Molecular medicine reports.

[46]  Ming Zhou,et al.  MiR-20a inhibits cutaneous squamous cell carcinoma metastasis and proliferation by directly targeting LIMK1 , 2014, Cancer biology & therapy.

[47]  Y. Tabuchi,et al.  A microRNA-27a mimic sensitizes human oral squamous cell carcinoma HSC-4 cells to hyperthermia through downregulation of Hsp110 and Hsp90. , 2014, International journal of molecular medicine.

[48]  Yun-peng Liu,et al.  miRNA423-5p regulates cell proliferation and invasion by targeting trefoil factor 1 in gastric cancer cells. , 2014, Cancer letters.

[49]  Zujiang Yu,et al.  Role of MicroRNA-1 in Human Cancer and Its Therapeutic Potentials , 2014, BioMed research international.

[50]  Jingyan Xie,et al.  Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA/B expression , 2014, Cellular and Molecular Immunology.

[51]  Ji-Xin Cheng,et al.  Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. , 2014, Cell metabolism.

[52]  F. Kisseljov.  MicroRNAs and cancer , 2014, Molecular Biology.

[53]  Taotao Ma,et al.  MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells. , 2013, Cellular signalling.

[54]  M. Kuo,et al.  MicroRNA-17/20a functions to inhibit cell migration and can be used a prognostic marker in oral squamous cell carcinoma. , 2013, Oral oncology.

[55]  Hua Yang,et al.  Involvement of miR-20a in Promoting Gastric Cancer Progression by Targeting Early Growth Response 2 (EGR2) , 2013, International journal of molecular sciences.

[56]  C. Shin,et al.  c‐Myc‐mediated overexpression of miR‐17‐92 suppresses replication of hepatitis B virus in human hepatoma cells , 2013, Journal of medical virology.

[57]  N. Seki,et al.  Aberrant expression of microRNAs in bladder cancer , 2013, Nature Reviews Urology.

[58]  C. Croce,et al.  Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2 , 2013, Proceedings of the National Academy of Sciences.

[59]  D. Yao,et al.  Aberrant expression of miR-20a and miR-203 in cervical cancer. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[60]  L. Zhong,et al.  Decrease expression of microRNA-20a promotes cancer cell proliferation and predicts poor survival of hepatocellular carcinoma , 2013, Journal of experimental & clinical cancer research : CR.

[61]  X. Chen,et al.  Increased serum and urinary microRNAs in children with idiopathic nephrotic syndrome. , 2013, Clinical chemistry.

[62]  T. Hijikata,et al.  MicroRNA-1 targets Slug and endows lung cancer A549 cells with epithelial and anti-tumorigenic properties. , 2013, Experimental cell research.

[63]  W Abou-Kheir,et al.  MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms , 2013, Oncogene.

[64]  J. Utikal,et al.  Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[65]  F. Slack,et al.  miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. , 2012, Cancer research.

[66]  Pengyuan Yang,et al.  MicroRNA-1 inhibits proliferation of hepatocarcinoma cells by targeting endothelin-1. , 2012, Life sciences.

[67]  Shadan Ali,et al.  MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer , 2012, British Journal of Cancer.

[68]  B. Song,et al.  Suppression of CX43 expression by miR-20a in the progression of human prostate cancer , 2012, Cancer biology & therapy.

[69]  Xi Chen,et al.  Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. , 2012, Clinical chemistry.

[70]  M. Gariboldi,et al.  miRNA Profiling in Colorectal Cancer Highlights miR-1 Involvement in MET-Dependent Proliferation , 2012, Molecular Cancer Research.

[71]  N. Seki,et al.  microRNA-1/133a and microRNA-206/133b clusters: Dysregulation and functional roles in human cancers , 2012, Oncotarget.

[72]  Nicolás Peláez,et al.  Biological robustness and the role of microRNAs: a network perspective. , 2012, Current topics in developmental biology.

[73]  O. Mariani,et al.  miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response , 2011, Nature Medicine.

[74]  Yingjun Zhao,et al.  MicroRNA-423 promotes cell growth and regulates G(1)/S transition by targeting p21Cip1/Waf1 in hepatocellular carcinoma. , 2011, Carcinogenesis.

[75]  Min Liu,et al.  miRNA‐1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line , 2011, FEBS letters.

[76]  A. Fusco,et al.  MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1alpha. , 2011, The Journal of clinical endocrinology and metabolism.

[77]  Igor Pogribny,et al.  Small molecules with big effects: the role of the microRNAome in cancer and carcinogenesis. , 2011, Mutation research.

[78]  Xiaohong Zhao,et al.  Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells , 2011, Journal of experimental & clinical cancer research : CR.

[79]  Xi Chen,et al.  A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. , 2011, European journal of cancer.

[80]  K. Kelnar,et al.  The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. , 2011, Nature medicine.

[81]  Wenlin Huang,et al.  MicroRNA-20a overexpression inhibited proliferation and metastasis of pancreatic carcinoma cells. , 2010, Human gene therapy.

[82]  Jing Cai,et al.  MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. , 2010, Gynecologic oncology.

[83]  Dong Wang,et al.  Human MicroRNA Oncogenes and Tumor Suppressors Show Significantly Different Biological Patterns: From Functions to Targets , 2010, PloS one.

[84]  H. Hermeking.  The miR-34 family in cancer and apoptosis , 2010, Cell Death and Differentiation.

[85]  Hongwei Zhang,et al.  Down-Regulation of miR-27a Might Reverse Multidrug Resistance of Esophageal Squamous Cell Carcinoma , 2010, Digestive Diseases and Sciences.

[86]  C. V. D. Velde,et al.  Gastric cancer – Authors' reply , 2009, The Lancet.

[87]  J. Qu,et al.  MicroRNA-1/206 Targets c-Met and Inhibits Rhabdomyosarcoma Development* , 2009, The Journal of Biological Chemistry.

[88]  E. Wagner,et al.  Signal integration by JNK and p38 MAPK pathways in cancer development , 2009, Nature Reviews Cancer.

[89]  B. White,et al.  Coordinate Regulation of FOXO1 by miR-27a, miR-96, and miR-182 in Breast Cancer Cells , 2009, The Journal of Biological Chemistry.

[90]  John T. Wei,et al.  PROSTATE CANCER DETECTION USING A NOVEL COMPUTERIZED THREE-DIMENSIONAL PROSTATE BIOPSY TEMPLATE (TARGETSCAN™): RESULTS OF A MULTICENTER PROSPECTIVE DATA REGISTRY , 2009 .

[91]  Huaiyu Mi,et al.  PANTHER pathway: an ontology-based pathway database coupled with data analysis tools. , 2009, Methods in molecular biology.

[92]  Xiuping Liu,et al.  Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. , 2008, Biochemical pharmacology.

[93]  Frank J. Slack,et al.  MicroRNAs and cancer: An overview , 2008, Cell cycle.

[94]  Yoshihiro Yamanishi,et al.  KEGG for linking genomes to life and the environment , 2007, Nucleic Acids Res..

[95]  Y. Yamaoka,et al.  Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. , 2008, Internal medicine.

[96]  G. Guyatt,et al.  Citrus fruit intake and stomach cancer risk: a quantitative systematic review , 2008, Gastric Cancer.

[97]  Gregory J. Hannon,et al.  microRNAs join the p53 network — another piece in the tumour-suppression puzzle , 2007, Nature Reviews Cancer.

[98]  Brad T. Sherman,et al.  The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists , 2007, Genome Biology.

[99]  A. Barabasi,et al.  Human disease classification in the postgenomic era: A complex systems approach to human pathobiology , 2007, Molecular systems biology.

[100]  S. Tsugane,et al.  Diet and the risk of gastric cancer: review of epidemiological evidence , 2007, Gastric Cancer.

[101]  David Baltimore,et al.  MicroRNA-155 is induced during the macrophage inflammatory response , 2007, Proceedings of the National Academy of Sciences.

[102]  Nan Guo,et al.  PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways , 2006, Nucleic Acids Res..

[103]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[104]  Y. Ikeda,et al.  962. The Ras/Raf-1/MEK/ERK Signaling Pathway Dictates Host Cell Permissiveness to VSV Infection , 2006 .

[105]  N. Hayward,et al.  Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS , 2005, British Journal of Cancer.

[106]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.

[107]  C. Croce,et al.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[108]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[109]  Michael L. Gatza,et al.  Cellular Transformation by the HTLV-I Tax Protein, a Jack-of-All-Trades , 2003, Oncogene.

[110]  J. Dancey.  Agents targeting ras signaling pathway. , 2002, Current pharmaceutical design.

[111]  H. Espejo,et al.  [Gastric cancer]. , 1996, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.